Ben and Catherine Ivy Center for Advanced Brain Tumor Treatment at PSNI collaborates with Seattle-based HDT Bio on preparations for trialing novel treatment to breach blood-brain barrier, and deliver proprietary immunotherapeutic directly into patients' tumors, rather than intravenously June 9, 2026 -- A collaboration involving Providence Swedish Neuroscience Institute (PSNI) recently concluded initial testing of a novel immunotherapy research project for the treatment of glioblastoma (GBM). Th

The U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation to opaganib1 for the treatment of neuroblastoma, a type of cancer most commonly affecting babies and young children Rare pediatric disease designation provides for a Priority Review Voucher (PRV) subject to certain conditions This new designation is in addition to opaganib's current neuroblastoma orphan drug designation, providing for potential benefits such as accelerated development and review times, F

June 8, 2026 -- Foresee Pharmaceuticals (6576.TWO), ("Foresee") announced today that Foresee's oral ALDH2 activator, mirivadelgat, has been selected to enter clinical testing in Parkinson's disease in the SLEIPNIR Phase 2a platform trial, in collaboration with Haukeland University Hospital, Bergen, Norway. SLEIPNIR is a multi-arm Phase 2a clinical trial platform designed to evaluate investigational disease-modifying therapies in Parkinson's disease, with focus on brain penetration, biological ta

June 8, 2026 - Kye Pharmaceuticals Inc. ("Kye"), a Canadian-based specialty pharmaceutical company focused on licensing and commercializing innovative medicines for patients in Canada, today announced that Dyanavel® XR (amphetamine extended-release) tablets are now available through pharmacies and wholesalers nationwide. Dyanavel® XR is authorized for sale in Canada for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults aged 18 years and older, as well as in children age

June 8, 2026 -- Argo Biopharmaceutical Co., Ltd. (Argo Biopharma), a clinical-stage small interfering RNA (siRNA) therapeutics company, has been selected to present Phase II updated results for BW-20805 at the European Association of Allergy & Clinical Immunology (EAACI) 2026 Congress, being held on June 12-15, 2026 in Istanbul, Türkiye. BW-20805 is an investigational siRNA therapy that targets and significantly inhibits prekallikrein (PKK), a well-validated target for hereditary angioedema (HA

June 8, 2026 --Curasight A/S ("Curasight" or "the Company") (Spotlight: CURAS) announces encouraging preliminary readout from its Phase 1 clinical trial with uTREAT® in patients with aggressive brain cancer (glioblastoma). A preliminary readout of the Phase 1 clinical trial with uTREAT® in glioblastoma, an aggressive brain cancer, has now been undertaken. The data support: The feasibility and safety of the mode of administration, super-selective intra-arterial cerebral injection (super-SIACI) w

– Preclinical NHP data demonstrate significant fat‑specific weight loss with RV‑8451, while preserving lean mass and showing no gastrointestinal adverse events – IND‑enabling studies advancing, with IND submission for RV-8451in obesity targeted for Q1 2027 – Greater fat loss in head-to-head NHP study versus orforglipron while preserving lean mass June 5, 2026 – Rivus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on advancing cardiometabolic health, today announced pr

New real-world survey data reveal the daily impact of Huntington’s disease (HD) chorea, with over 68% of patients reporting interference with social life or emotional wellbeing1 and up to 83% of caregivers noting impact on their own daily lives.2 Following treatment with AUSTEDO or AUSTEDO XR, most patients (60-71%) reported improvement across multiple quality of life domains as a result of their improved movements.1 As a result of the patient’s reduced chorea impact, most caregivers reported l

Biogen has announced that salanersen has been given the US FDA Breakthrough Therapy Designation to treat spinal muscular atrophy (SMA).Salanersen is an investigational novel antisense oligonucleotide (ASO) and has the potential to offer high efficacy in SMA with once-yearly dosing. Breakthrough Therapy designation helps to speed up the development and review of drugs intended to treat serious conditions, and where preliminary clinical evidence indicates that the drug may demonstrate substantial

Investigational results from FIND-CKD provide full efficacy and safety data and is the fifth consecutive Phase III clinical trial where KERENDIA met its primary endpoint—adding to a clinical trial program of more than 20,000 patients across multiple patient populations with heart and kidney diseases, now with additional data in a different patient population.1 KERENDIA is currently approved by the FDA for use in adults with chronic kidney disease (CKD) associated with type 2 diabetes (T2D), as